Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.

Alessandro Costa Elisabetta Abruzzese Roberto Latagliata Olga MulasIda CarmosinoEmilia ScalzulliMaria Laura BisegnaClaudia IeloMaurizio MartelliGiovanni Caocci Massimo Breccia

Published in: Journal of clinical medicine (2024)

TKIs appear to be safe and effective even in very elderly CML patients, and dose optimization strategies yield satisfactory molecular responses for adequate disease control with an improved safety profile.

Keyphrases

chronic myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
middle aged
patient reported
community dwelling